← VERU INC. (VERU) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
VERU INC. (VERU)
Pharmaceutical Preparations · market cap $42M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Veru Inc. (VERU) is a micro-cap pharmaceutical company with a $37M market cap and approximately $27.6M in cash, implying a runway of roughly 5.5 months. Its lead asset, Veru-111, is in Phase 3 development for Adult Respiratory Distress Syndrome (ARDS), with a pipeline that also includes Phase 2 programs in metastatic prostate cancer (Veru-944), muscle loss (Enobosarm), and obesity (semaglutide weekly injection). The company has been burning cash at roughly $16–51M annually in R&D and has posted significant net losses each year since 2022.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Veru-944 | Phase 2 | Prostate Cancer Metastatic |
| Enobosarm | Phase 2 | Muscle Loss |
| Veru-111 | Phase 3 | Respiratory Distress Syndrome, Adult |
Price & technical context
3-month
-15.8%
6-month
+20.4%
12-month
-28.1%
52-wk range
$2.09–$4.43
vs 50-day MA
+6.1%
vs 200-day MA
+6.7%
Realized vol
91.7%
Max drawdown
-83.7%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VERU (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.